Does angiotensin-converting enzyme inhibition improve the energetic status of cardiac and skeletal muscles in heart failure induced by aortic stenosis in rats?

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 4, 2003, Pages 399-407

  Momken, Iman ^a   Kahapip, Jules ^a   Bahi, Lahoucine ^a   Badoual, Thierry ^b   Hittinger, Luc ^b   Ventura Clapier, Renée ^a   Veksler, Vladimir ^a  

^a INSERM   (France)

^b FACULTÉ DE MÉDECINE   (France)

Author keywords

Energy metabolism; Mitochondria; Perindopril; Ventricular hypertrophy

Indexed keywords

ANGIOTENSIN; CITRATE SYNTHASE; CREATINE KINASE; CYTOCHROME C OXIDASE; DIPEPTIDYL CARBOXYPEPTIDASE; LACTATE DEHYDROGENASE; PERINDOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CLAMPING; AORTA STENOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART WORK; HEMODYNAMICS; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; SYSTOLE; VASODILATATION;

EID: 0037384836     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00044-0     Document Type: Article

References (49)

1. Katz AM. Heart failure: pathophysiology, molecular biology and clinical management. Philadelphia, USA: Lippincott Williams & Wilkins, 2000.
2. Magnusson G., Kaijser L., Rong H., Isberg B., Sylven C., Saltin B. Exercise capacity in heart failure patients: relative importance of heart and skeletal muscle. Clin Physiol. 16:1996;183-195.
3. Neubauer S., Horn M., Cramer M., Harre K., Newell J.B., Peters W., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 96:1997;2190-2196.
4. De Sousa E., Veksler V., Minajeva A., Kaasik A., Mateo P., Mayoux E., et al. Subcellular creatine kinase alterations. Implications in heart failure. Circ Res. 85:1999;68-76.
5. Lopaschuk G.D., Rebeyka I.M., Allard M.F. Metabolic modulation: a means to mend a broken heart. Circulation. 105:2002;140-142.
6. Massie B., Conway M., Yonge R., Frostick S., Ledingham J., Sleight P., et al. Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow. Circulation. 76:1987;1009-1019.
7. Drexler H., Riede U., Munzel T., Konig H., Funke E., Just H. Alterations of skeletal muscle in chronic heart failure. Circulation. 85:1992;1751-1759.
8. Kemp G.J., Thompson C.H., Stratton J.R., Brunotte F., Conway M., Adamopoulos S., et al. Abnormalities in exercising skeletal muscle in congestive heart failure can be explained in terms of decreased mitochondrial ATP synthesis, reduced metabolic efficiency, and increased glycogenolysis. Heart. 76:1996;35-41.
9. De Sousa E., Veksler V., Bigard X., Mateo P., Ventura-Clapier R. Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. Circulation. 102:2000;1847-1853.
10. De Sousa E., Veksler V., Bigard X., Mateo P., Serrurier B., Ventura-Clapier R. Dual influence of disease and increased load on diaphragm muscle in heart failure. J Mol Cell Cardiol. 33:2001;699-710.
11. Zimmerman B.G., Sybertz E.J., Wong P.C. Interaction between sympathetic and renin-angiotensin system. J Hypertens. 2:1984;581-587.
12. 1 receptor. Am J Hypertens. 5:1992;276-280.
13. Sadoshima J., Xu Y., Slayter H.S., Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 75:1993;977-984.
14. Gordon S.E., Davis B.S., Carlson C.J., Booth F.W.A.N.G. II is required for optimal overload-induced skeletal muscle hypertrophy. Am J Physiol. 280:2001;E150-159.
15. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
16. Montgomery H., Brull D. Gene-environment interactions and the response to exercise. Int J Exp Pathol. 81:2000;283-287.
17. Vescovo G., Dalla Libera L., Serafini F., Leprotti C., Facchin L., Volterrani M., et al. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 98:1998;1742-1749.
18. Mettauer B., Zoll J., Sanchez H., Lampert E., Ribera F., Veksler V., et al. Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active control subjects. J Am Coll Cardiol. 38:2001;947-954.
19. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation. 97:1998;1411-1420.
20. Cox N.L., Abdul-Hamid A.R., Mulley G.P. Why deny ACE inhibitors to patients with aortic stenosis? Lancet. 352:1998;111-112.
21. Rimington H., Takeda S., Chambers J. Aortic stenosis and ACE inhibitors. Lancet. 352:1998;820-821.
22. Poullis M. Aortic stenosis and ACE inhibitors. Lancet. 352:1998;821.
23. Cox N.L., Abdul-Hamid A.R., Mulley G.P. Aortic stenosis and ACE inhibitors. Lancet. 352:1998;1392.
24. Dzau V.J., Bernstein K., Celermajer D., Cohen J., Dahlof B., Deanfield J., et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. L-20L. Am J Cardiol. 88:((Suppl):1):2001.
25. Feldman A.M., Weinberg E.O., Ray P.E., Lorell B.H. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res. 73:1993;184-192.
26. Veksler V.I., Kuznetsov A.V., Sharov V.G., Kapelko V.I., Saks V.A. Mitochondrial respiratory parameters in cardiac tissue: a novel method of assessment by using saponin-skinned fibers. Biochim Biophys Acta. 892:1987;191-196.
27. Veksler V.I., Kuznetsov A.V., Anflous K., Mateo P., van Deursen J., Wieringa B., et al. Muscle creatine kinase-deficient mice. II. Cardiac and skeletal muscles exhibit tissue-specific adaptation of the mitochondrial function. J Biol Chem. 270:1995;19921-19929.
28. Welsch C., Grima M., Giesen E.M., Helwig J.J., Barthelmebs M., Coquard C., et al. Assay of tissue angiotensin converting enzyme. J Cardiovasc Pharmacol. 14:(Suppl 4):1989;S26-31.
29. Nussberger J., Brunner D.B., Waeber B., Brunner H.R. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension. 8:1986;476-482.
30. Wharton D.C., Tzagoloff A. Cytochrome oxidase from beef heart mitochondria. Meth Enzymol. 10:1967;245-250.
31. Zierhut W., Zimmer H.G., Gerdes A.M. Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats. Circ Res. 69:1991;609-617.
32. Litwin S.E., Katz S.E., Weinberg E.O., Lorell B.H., Aurigemma G.P., Douglas P.S. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation. 91:1995;2642-2654.
33. Grima M., Ingert C., Michel B., Barthelmebs M., Imbs J.L. Renal tissue angiotensins during converting enzyme inhibition in the spontaneously hypertensive rat. Clin Exp Hypertens. 19:1997;671-685.
34. Bruckschlegel G., Holmer S.R., Jandeleit K., Grimm D., Muders F., Kromer E.P., et al. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 25:1995;250-259.
35. Weinberg E.O., Schoen F.J., George D., Kagaya Y., Douglas P.S., Litwin S.E., et al. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 90:1994;1410-1422.
36. 1 receptor antagonist, and surgical reversal. J Cardiovasc Pharmacol. 23:1994;291-299.
37. Turcani M., Rupp H. Heart failure development in rats with ascending aortic constriction and angiotensin-converting enzyme inhibition. Br J Pharmacol. 30:2000;1671-1677.
38. 1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation. 95:1997;1592-1600.
39. Turcani M., Rupp H. Development of pressure overload induced cardiac hypertrophy is unaffected by long-term treatment with losartan. Mol Cell Biochem. 188:1998;225-233.
40. Baba H.A., Iwai T., Bauer M., Irlbeck M., Schmid K.W., Zimmer H.G. Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats. J Mol Cell Cardiol. 31:1999;445-455.
41. Schieffer B., Wirger A., Meybrunn M., Seitz S., Holtz J., Riede U.N., et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 89:1994;2273-2282.
42. Liu Y.H., Yang X.P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 99:1997;1926-1935.
43. Sanbe A., Tanonaka K., Kobayasi R., Takeo S. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol. 27:1995;2209-2222.
44. Hugel S., Horn M., de Groot M., Remkes H., Dienesch C., Hu K., et al. Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol. 277:1999;H2167-2175.
45. Nascimben L., Friedrich J., Liao R., Pauletto P., Pessina A.C., Ingwall J.S. Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Circulation. 91:1995;1824-1833.
46. Vescovo G., Dalla Libera L., Serafini F., Leprotti C., Facchin L., Volterrani M., et al. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 98:1998;1742-1749.
47. Guazzi M., Palermo P., Pontone G., Susini F., Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol. 84:1999;1038-1043.
48. Schaufelberger M., Andersson G., Eriksson B.O., Grimby G., Held P., Swedberg K., et al. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J. 17:1996;1678-1685.
49. Yamaguchi F., Kawana K., Tanonaka K., Kamano I., Igarashi T., Gen E., et al. Improvement of exercise capacity of rats with chronic heart failure by long-term treatment with trandolapril. Br J Pharmacol. 126:1999;1585-1592.